Inflammatory bowel disease in Korea: epidemiological, genomic, clinical, and therapeutic characteristics by 源��썝�샇 & 源����닔
Review
Gut and Liver, Vol. 4, No. 1, March 2010, pp. 1-14
Correspondence to: Won Ho Kim
Department of Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, 134, Shinchon-dong, Seodaemun- 
gu, Seoul 120-752, Korea
Tel: +82-2-2228-1950, Fax: +82-2-393-6884, E-mail: kimwonho@yuhs.ac
Received on October 1, 2009. Accepted on October 4, 2009.
DOI: 10.5009/gnl.2010.4.1.1
Inflammatory Bowel Disease in Korea: Epidemiological, Genomic, 
Clinical, and Therapeutic Characteristics
Eun Soo Kim and Won Ho Kim
Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea
Inflammatory bowel disease (IBD) describes chronic 
inflammatory disease of the intestines and has a vari-
able course; Crohn’s disease and ulcerative colitis 
comprise the two main forms of the condition. 
Although IBD occurs worldwide, its epidemiologic and 
clinical characteristics vary depending upon the geo-
graphic location and the ethnicity of the population. 
Identifying the characteristic features of IBD in pop-
ulations living in different geographical locations and 
with different ethnicities may provide significant clues 
about its etiology and pathophysiology, which in turn 
may be helpful in the development of more appro-
priate treatment strategies for IBD for these different 
populations. Therefore, it is important for each country 
and region to evaluate critically the epidemiology, ge-
nomics, and clinical characteristics of IBD among its 
own population. We have performed a critical review 
of the recent data in Korea, and describe herein the 
current epidemiologic and genotypic status, as well as 
the clinical manifestations and therapeutic responses 
of IBD that are unique to Korean patients. (Gut Liver 
2010;4:1-14)
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INTRODUCTION
  Inflammatory bowel disease (IBD) is a chronic relapsing 
inflammatory disorder of the bowel, consisting mainly of 
Crohn’s disease (CD) and ulcerative colitis (UC). The in-
cidence of IBD has been rising not only in Western coun-
tries, but also in Asia, including Korea.1 Intriguingly, the 
characteristics of Western and Asian IBD patients differ 
in epidemiology, phenotype and genetic susceptibility.2-7 
Evaluating these geographically unique features may pro-
vide substantial clues for identifying the pathophysiology 
and the etiology of IBD. However, such efforts have been 
challenging in most Asian countries, where there are lack 
of population-based registries, limited access to health 
care facilities, limited availability of diagnostic devices, 
and the occurrence of infectious diseases that mimic IBD, 
which hindered the accurate assessment of the incidence 
and the prevalence, the risk factors and the clinical char-
acteristics of IBD.8 Until recently, only Japan has been 
able to report the reliable data, as it has the accessible 
and efficient health care system and maintains a national 
IBD registry under the Ministry of Health, Labor and 
Welfare.3 In Korea, the Korean Association for the Study 
of Intestinal Diseases (KASID) has recently taken a lead-
ing role in establishing the organizational structural bases 
for investigating IBD and has performed a series of na-
tionwide studies.1,9,10 Korea has a relatively small nation 
of territory and the population is ethnically homogeneous. 
Members of KASID from each province of the nation par-
ticipate to perform multicenter studies and patients with 
IBD have been registered by members of KASID.1,9 This 
review will describe the updated data on Korean IBD pa-
tients based on the recent publications.1,8,11-20
EPIDEMIOLOGY
  Despite the advances in scientific technologies used to 
study IBD, its etiology and pathogenesis remain unclear. 
Traditionally, it has generally been thought that IBD oc-
curs predominantly in the industrialized Western coun-
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Table 1. Differential Diagnosis of Intestinal Inflammation
Self limited colitis
Diverticulitis
Intestinal tuberculosis
Ischemic colitis
Intestinal Behçet’s disease
Radiation colitis
Amebic colitis
Bacterial infectious colitis
Cytomegalovirus colitis
Appendicitis
Eosinophilic gastroenteritis
Henoch-Schonlein purpura
Graft-versus-host disease
Diversion colitis
Microscopic colitis
Gastrointestinal sarcoidosis
Drug-related (NSAIDs, diuretics, antihypertensives)
tries. However, as many other parts of the world includ-
ing Asia, South America and Eastern Europe became in-
dustrialized since the middle of the last century, the in-
cidence and the prevalence of IBD in these areas in-
creased dramatically, suggesting that urbanization may be 
a risk factor for IBD.2,3,8,21-27 On the other hand, in 
Western Europe and North America, the incidence and 
the prevalence of IBD have stabilized or only slightly in-
creased over time.28-31 
  In Korea, the incidence and prevalence of CD and UC 
are low compared to those of Western countries, but are 
increasing rapidly. According to a recent update on the 
descriptive epidemiology of IBD in Korea1 based on the 
population-based data from an urban district in Seoul, the 
mean annual incidence rates of CD and UC increased 
from 0.05 to 0.34 per 100,000 inhabitants in 1986-1990, 
and from 1.34 to 3.08 per 100,000 inhabitants in 
2001-2005, respectively. The adjusted prevalence rates of 
CD and UC per 100,000 inhabitants were 11.24 (95% CI, 
9.29-13.18) and 30.87 (95% CI, 27.47-34.27), respecti-
vely. In addition, it was observed that the ratio of the in-
cidence rates of UC to CD was decreasing in Korea, in-
dicating that CD showed a trend of more accelerated in-
cidence rate compared to UC. This finding is similar to 
that observed in many Western countries.28,32,33 Male pre-
dominance in the prevalence rate of CD was observed in 
the Korean population, a finding similar to those reported 
in the recent studies from China2 and Japan34 while the 
incidence of CD in females is predominant or equal to 
that in males in Western countries.28,32 
DIAGNOSIS
  Regarding the diagnosis of IBD, two factors should be 
considered: first, distinguishing IBD patients from alter-
native inflammatory disease patients and secondly, cor-
rectly differentiating between UC and CD.35 Before estab-
lishing a diagnosis of IBD, other various forms of in-
testinal inflammation with identifiable causes should be 
excluded using relevant history, careful physical examina-
tion, prudent laboratory tests, and thorough review of the 
radiographic, endoscopic and pathologic data. The differ-
ential diagnosis of intestinal inflammation is outlined in 
Table 1. In some Asian countries including Korea, where 
intestinal tuberculosis is still prevalent, the distinction 
between intestinal tuberculosis and CD is extremely diffi-
cult because of their clinical similarities. Studies from 
Korea have shown that the proportion of patients receiv-
ing anti-tuberculosis treatment before confirmation of CD 
was nearly 50% of all CD patients.36 In a study conducted 
in Korea, four endoscopic characteristics were identified 
for each disease: anorectal lesions, longitudinal ulcers, 
aphthous ulcers, and a cobblestone appearance for CD, 
and involvement of fewer than four segments, a patulous 
ileocecal valve, transverse ulcers, and scars or pseudopo-
lyps for intestinal tuberculosis. Using these endoscopic 
parameters, the diagnosis of either intestinal tuberculosis 
or CD was correctly made in 87.5% of patients.18 In Asia, 
if a patient has an ulceration in the ileocecal region, in-
testinal Behçet’s disease (BD) should be included as a dif-
ferential diagnosis.35 In an effort to differentiate intestinal 
BD and CD, a Korean study reported that round ulcer-
ations, ≤5 in number, focal distributions, and absence of 
aphthous and cobblestone lesions were dominant features 
in intestinal BD.12 The authors stated that these charac-
teristics enabled the correct diagnosis of intestinal BD or 
CD in 92% of patients with ulcers on colonoscopy. 
  As the two main subforms of IBD, UC and CD have 
similar clinical manifestations, it is very challenging for 
the clinicians to correctly diagnose IBD. While there are 
several diagnostic criteria available for IBD including 
Mendeloff’s criteria,37 Lennard-Jones criteria,38 the inter-
national multicentre scoring system of the Organization 
Mondiale de Gastroenterologie (OMGE),39 and the diag-
nostic criteria of the Japanese Research Society on IBD,3 
there is no single gold standard for the diagnosis of IBD. 
All diagnostic criteria use an integrating assessment of 
the clinical presentation, endoscopic, radiographic, and 
pathologic findings for diagnosis. More recently, serologic 
assays, utilizing antineutrophil cytoplasmic autoantibody 
(ANCA) and anti-Saccharomyces cerevisiae antibody (ASCA) 
have been added as diagnostic tools with an adjunctive 
role in differentiating UC and CD.40,41 A Korean study 
demonstrated that the sensitivity (49.4%) and the specif-
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Table 2. Differences in Clinical, Endoscopic, and Histological Features between Ulcerative Colitis and Crohn’s Disease
Ulcerative colitis Crohn’s disease
Hematochezia Common Rarely
Palpable abdominal mass Rarely Occasionally in right lower abdomen
UGI involvement No Yes
Distribution Diffuse and continuous Focal and asymmetric with skip segments
Fistulas and abscesses Rarely Common 
Strictures Rarely Common 
Perianal lesion Rarely Common 
Mucosal appearance Diffuse friability, large ulcers Aphthous ulcers, linear or serpiginous, cobblestone ulcers
Granulomas Absent 15-60% present
Crypt abscesses Common May be present
Fissures Rarely Common 
Transmural mucosal inflammation No Yes
ANCA Common Rarely 
ASCA Rarely Common
UGI, upper gastrointestinal; ANCA, anti-neutrophil cytoplasmic antibodies; ASCA, anti-saccharomyces cerevisiae antibodies.
icity (79.2%) of ASCA for CD are comparable to those 
seen in Western countries and that the sensitivity 
(44.2%) and the specificity (95.8%) of the pANCA for 
UC are also similar to those previously reported in 
Western countries.42 However, in a recent Korean study, 
Lee et al. reported that the prevalence of pANCA in 
Korean patients with UC was relatively low compared to 
patients in Western countries (22% vs 59-84%).17 The 
major distinctive clinical, morphological, structural and 
pathological features between the two subforms of IBD 
are listed in Table 2. 
As genome-wide association studies have been in-
troduced in an effort to identify the etiologic factors of 
IBD, many genetic polymorphisms related to an increased 
risk of IBD have been discovered.43-52 In the near future, 
it is expected that a more specific genetic map will be 
identified to improve the diagnosis of IBD. Combined 
with serologic assays, genetic testing is promising for a 
number of reasons. First, genetic testing is non-invasive. 
Second, genetic testing can be used to predict the pheno-
typic features of disease.53 Serologic tests serve as effec-
tive means to predict a complicated course of the disease 
by showing high associations with disease activity and the 
sites of involvement in IBD.54,55 A judicious combined uti-
lization of genetic and serologic tests may be more reli-
able for predicting complicated behavior than the use of 
either test alone and may be helpful in developing a 
risk-stratified approach for the selection of medical 
therapy.56 Moreover, genetic evidence could allow clini-
cians to identify IBD patients before they become sympto-
matic and to choose appropriate early preventive 
measures.
  Genotypic features and clinical characteristics of Korean 
IBD are somewhat different from those of Western 
countries. In Korea, a recent population based study 
showed that the most common location of the involve-
ment CD is in both small bowel and colon (66.7%) fol-
lowed by isolated segments of either small bowel (21.0%) 
or colon (12.3%).1 This finding is similar to that reported 
by a Japanese study.57 This contrasts with recent Euro-
pean studies that reported isolated colonic disease as the 
most common type of CD at diagnosis.29,58 In a genetic 
polymorphism study with a large number of Northern 
European and Korean patients with CD and normal con-
trols, CARD15 (NOD2) mutations were not found to be 
associated with susceptibility to CD in Korean patients, 
although they were in European populations.59 This find-
ing was confirmed by another study also conducted in 
Korea.15 On the other hand, recent studies showed that 
genetic variants in IL23R, tumor necrosis factor superfamily 
member 15 (TNFSF15), and tumor necrosis factor-α 
(TNF-α) gene but not autophagy-related 16-like 1 
(ATG16L1), which are known to be associated with CD 
in European populations also contribute to CD suscepti-
bility in Koreans.60-62 In Japan63,64 and Korea65 studies, the 
HLA-DRB1*1502 allele was shown to be positively asso-
ciated with UC, whereas the results showed discord 
about this association in Western populations.66-68 
  The clinical features of UC at diagnosis are reported to 
be similar in Koreans and Westerners.20 For instance, 
there are no differences in the extent and the severity of 
disease at diagnosis or in the male to female ratio of pa-
tients with UC between Korea and Western countries. 
EVALUATION OF CLINICAL ACTIVITY
  To develop an optimal treatment strategy for IBD, it is 
essential to fully understand the disease’s activity and ex-
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Table 3. The Vienna and Montreal Classifications of Crohn’s Disease
Montreal Vienna
Age at diagnosis A1, ≤16 years A1, ＜40 years
16 years＜A2≤40 years A2, ≥40 years
A3, 40 years ＜
Location L1, Terminal ileum L1, Terminal ileum
L2, Colon L2, Colon
L3, Ileocolon L3, Ileocolon
L4, Isolated upper gastrointestinal L4, Upper gastrointestinal
Behavior B1, Non-stricturing non-penetrating B1, Non-stricturing non-penetrating
B2, Stricturing B2, Stricturing
B3, Penetrating B3, Penetrating
p perianal disease modifier
tension of disease. The Truelove and Witts severity index 
is one of the most commonly used disease activity in-
dexes for UC, and comprises six items: number of stools 
per day, presence of blood in stools, temperature, pulse, 
hemoglobin and erythrocyte sedimentation rate (ESR).69 
Another popular activity index is the Mayo Score, which 
is composed of four variables: frequency of bowel move-
ments, rectal bleeding, findings of sigmoidoscopy and 
Physician Global Assessment.70 Generally, the anatomic 
extent of UC is divided into “distal” when the lesions are 
not found beyond the splenic flexure and “extensive” 
when the mucosal inflammation is extended proximally to 
the splenic flexure.71 In a Korean study of 304 UC pa-
tients, 44.1% of patients were diagnosed with proctitis, 
22.7% with left side colitis and 33.2% with extensive 
colitis. The clinical severity was mild in 49.0% of pa-
tients, moderate in 41.1% and severe in 8.6%.20 As sero-
logic markers for the clinical activity of UC, pANCA and 
triggering receptors expressed on myeloid cells-1 (TREM-1) 
have been reported to be useful. The UC activity index 
was found to be higher in pANCA-positive patients than 
in pANCA-negative Korean patients.17 The serum TREM-1 
level correlated better with disease activity than ESR or 
CRP, irrespective of disease extent in Korean patients 
with UC.19 
  Since CD affects various sites of the intestine and man-
ifests as different endoscopic appearances of involvement, 
it is suggested that CD is a heterogeneous entity and that 
different genetic backgrounds may explain the different 
clinical patterns observed for the disease.72,73 It is, there-
fore, important to develop a simple classification of CD 
based on stable and reproducible clinical variables in or-
der to study its genetic or environmental bases. In 1998, 
the World Gastroenterology Meeting in Vienna proposed 
a new classification based on three clinical variables in-
cluding age at diagnosis, location and disease behavior 
(Table 3).74 According to the Vienna classification, pa-
tients are categorized into the A1 group if the diagnosis 
is made before 40 years of age and A2 if it is made 
thereafter. Patients are regarded as L1 when the disease 
is located in the terminal ileum, L2 when it is located in 
the colon, L3 when it is located in the ileocolon, and L4 
when it involves the upper gastrointestinal tract. The B1 
group includes patients with non-stricturing non-penetrat-
ing disease, the B2 group includes patients with strictur-
ing disease, and the B3 group includes patients with pen-
etrating disease. Among these variables, disease location 
appears to remain stable, while significant sustained 
changes are noted in disease behavior over time.75 
Recently, the Vienna classification was revised and a new 
Montreal classification was proposed.76 Regarding age-of- 
onset, the Montreal revision categorizes early onset of 
disease as an A1 category for those with an age of diag-
nosis of 16 years or younger. With respect to disease lo-
cation, the Montreal classification allows upper gastro-
intestinal disease to coexist with more distal disease. 
Lastly, in terms of disease behavior, perianal disease is 
recognized as a separate subclassification. The data from 
Severance Hospital in Korea following the Vienna classi-
fication showed that patients in groups A1 and A2 made 
up 88.9% and 11.1%, respectively, of the entire patient 
population, and that L1, L2, L3, and L4 made up 19.5%, 
13.9%, 45.8%, and 20.8%, respectively.77 Notably, the 
most common location was L3, which is different from 
the pattern normally seen in Western countries. During 
the follow-up period, the proportion of B1 and B2 dimin-
ished from 48.6% and 27.8% to 37.5% and 25%, re-
spectively, while that of B3 increased from 23.6% up to 
37.5% (Fig. 1). The Crohn’s disease activity index 
(CDAI), the most widely applied activity index for CD, 
consists of eight variables: the number of liquid stools, 
the extent of abdominal pain, general well-being, the oc-
currence of extraintestinal symptoms, the need for an-
ti-diarrheal drugs, the presence of abdominal masses, 
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Fig. 1. Changes in disease behavior in Korean CD patients 
according to the Vienna classification.
hematocrit and body weight.78 The range of scores is 0 to 
600 and in clinical trials, active CD is indicated when the 
CDAI score is over 150. As the CDAI has been frequently 
used in clinical trials over two decades and vigorously va-
lidated, this index is considered the gold standard for 
evaluation of disease activity.79 The Harvey Bradshaw in-
dex is another convenient and commonly used activity in-
dex for CD.80 
MANAGEMENT OF IBD
  IBD is characterized by its chronicity, with cycles of re-
mission and relapse that occur over the patient’s lifetime. 
The goals of therapy for IBD, therefore, are not only the 
induction but also the maintenance of remission of symp-
toms without the use of corticosteroids. 
CROHN’S DISEASE
1. Medical management
1) Induction of remission
  Clinical trials have documented that sulfasalazine, bu-
desonide, and conventional corticosteroids are effective at 
inducing remission in mild to moderately active CD. 
  Although oral aminosalicylates have been widely used 
in clinical practice to treat active CD, their use is con-
troversial evidence. In the case of mild to moderate CD, 
clinical trials demonstrate that sulfasalazine administered 
at 2-6 g/day is more effective than placebo for inducing 
remission.81,82 This effect is most notable in patients with 
active colonic or ileocolonic disease.83,84 In contrast, mesa-
lazine has failed to show consistent results in various 
controlled studies.85-87 Some patients are intolerant of the 
adverse effects of sulfasalazine, including headache, nau-
sea, skin rash, fever, hepatitis, autoimmune hemolysis, 
aplastic anemia, leucopenia, folate deficiency, pancreatitis 
and male infertility. Most of these effects are related to 
the sulfapyridine moiety of sulfasalazine. Considering that 
the intestinal bacterial flora probably plays a role in the 
pathogenesis of CD, antibiotics have been used as ther-
apeutic agents. Although metronidazole and ciprofloxacin 
are often used for the treatment of CD, controlled trials 
have failed to show convincing evidence of their efficacy 
for the induction of remission in active CD.88-91 
Budesonide undergoes extensive first-pass hepatic metab-
olism, which reduces the side effects associated with sys-
temic corticosteroids. Well controlled studies have re-
vealed that budesonide is significantly more effective than 
placebo and 5-ASA, and is about as effective as conven-
tional corticosteroids for inducing remission in active 
CD.92-94 Therefore, budesonide has been recommended as 
a first-line therapy for mild to moderate CD of the ileum 
and proximal colon in an American Gastroenterological 
Association position statement and in the European 
Crohn’s and Colitis Organization Consensus.95,96 
  For those patients who do not respond to the first-line 
therapy described above and for those with moderate to 
severe CD, oral prednisone 40-60 mg/day should be 
given. In the case of fulminant and refractory in-
flammatory CD, remission may be induced with intra-
venous corticosteroids, such as methylprednisolone at 
1-1.5 mg/kg per day. A Korean study showed that serum 
albumin level could be a significant predictive factor for 
response to initial steroid therapy in active CD patients.97 
Compared to steroid responders, a steroid dependent 
group was characterized by lower serum albumin levels. 
According to the data from a Korean study, when a me-
dian dosage of oral steroids at 0.59 mg/kg was ad-
ministered, the overall response rates to the steroid at 
one month and one year were as high as 88.5% and 
58.3%, respectively.98 These rates were comparable to the 
best response rates from Western studies (Fig. 2). 
Patients with moderate to severe disease who fail to re-
spond to 5-ASA, budesonide and conventional cortico-
steroids, and patients intolerant of corticosteroids, may be 
treated with anti-TNF-α antibody agents including in-
fliximab (intravenous, 5 mg/kg at 0, 2, and 6 weeks) and 
adalimumab (subcutaneous, 160 mg at 0 and 80 mg at 2 
weeks). The results of a nationwide survey conducted in 
Korea,99 showed that the clinical response rate for in-
fliximab in luminal CD was 51%, and that the clinical re-
mission rate was 36%. Thirteen percent of patients did 
not respond to infliximab treatment. In patients with fist-
ular disease, the clinical response rate was 45%, clinical 
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Fig. 2. Overall response rates to 
steroids in Korean Crohn’s
disease patients.
remission 31%, and no response 24%. These results are 
similar to the clinical response rates reported in Western 
studies. Interestingly, the most common reason for in-
fliximab cessation in Korea was the limitation of the 
standard national health insurance reimbursement, as it 
previously covered only one year of infliximab treatment 
for active CD patients. However, the national health in-
surance coverage for infliximab has been extended up to 
28 injections, regardless of period in a recent amend-
ment.100 
2) Maintenance therapy
  Despite the widespread use of 5-ASA in clinical practice 
for the maintenance of medically induced remission in 
CD patients, this application is not evidence-based. 
Clinical studies have revealed that sulfasalazine and mesa-
lazine are not actually effective for maintaining medically 
induced remission in CD patients. In general, cortico-
steroids are not recommended for maintaining remission 
due to related systemic adverse effects and lack of 
efficacy. The results of a Korean study showed that pre-
operative corticosteroid treatment increased the risk of 
postoperative infections in patients with CD.101 Treatment 
with budesonide at 6 mg/day, however, has been shown 
to prolong the time to relapse and to be effective at 
maintaining remission for at least six months, but less 
than one year.102 
  Immunosuppressive agents such as azathioprine (AZA) 
and 6-mercaptopurine (6-MP) have been reported to be 
effective as maintenance therapy and to be advantageous 
for reducing or discontinuing steroid usage in ste-
roid-dependent CD patients.103-105 However, due to slow 
onset of action, these drugs are not used as induction 
therapy in patients with active CD.103 Because azathio-
prine or mercaptopurine are frequently continued indef-
initely as maintenance therapy,106 their long term side ef-
fects should be kept in mind. These agents, therefore, are 
currently reserved for steroid-dependent or refractory 
patients. Myelotoxicity is one of the significant adverse 
effects of thiopurine drugs and is reported to be asso-
ciated with decreased thiopurine methyltransferase 
(TPMT) and deficiency of inosine triphosphate py-
rophosphatase (ITPA).107 Korean patients with IBD who 
are treated with AZA/6-MP experience myelotoxicity 
more frequently than similarly treated Europeans. Among 
133 IBD patients treated with azathioprine in Korea, leu-
copenia occurred in 75 cases (56.4%), which is a higher 
incidence than that reported in Western studies.108 
Another Korean study revealed that there is no correla-
tion between TPMT genotype and AZA toxicity.109 
Methotrexate is another effective immunosuppressive 
agent for maintaining remission of CD. 
  For patients who are unable to maintain remission or 
who are dependent on steroids in spite of treatment with 
AZA or 6-MP, infliximab can be used for maintenance of 
remission, steroid-sparing and mucosal healing (5 mg/kg 
every eight weeks).110 Alternatively, adalimumab can be 
given subcutaneously for maintenance therapy at 40 mg 
every other week. With advances in the understanding of 
the pathophysiology of CD, a range of new therapeutic 
agents apart from anti-TNF drugs are under investigation. 
Among these innovative drugs are the T-cell blocking 
agents,111 anti-adhesion molecules,112 anti-vascular adhe-
sion protein-1 monoclonal antibody113 and avidity multi-
mers (avimers)114 with high ligand affinity and specificity 
that allows binding to many targets at the same time. 
2. Medical management of fistulizing CD
  One of the distinct characteristics of Korean CD pa-
tients is the high incidence of perianal fistulas. The in-
cidence rate of perianal fistulas in Korea is 48.5%, which 
is higher than that reported in other countries 
(13-38%).13 Because the incidence of CD in Korea has 
been increasing substantially, the possibility of CD should 
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be considered in Korean patients with perianal fistulas. 
The first-line therapy for fistulas in patients with CD is 
antibiotic treatment with metronidazole or cipro-
floxacin,96,104,115,116 with AZA or 6-MP being the typical 
second-line treatment. In cases in which active fistulizing 
disease fails to respond to treatment with antibiotics and 
immunosuppressive agents, infliximab or adalimumab can 
be administered.
3. Surgical management
  A significant proportion of CD patients will need surgi-
cal management an average of 20 years after diagnosis. 
Failure of medical therapy remains the most common in-
dication for surgical treatment of CD.117,118 The occur-
rence of complications despite medical treatment is an 
additional indication for surgical management.
  Worsening obstruction is a frequent complication of 
CD, especially with small bowel involvement. Whereas 
acute obstructions are often resolved with medical treat-
ment, chronic obstructions are usually caused by fi-
brostenotic lesions and require surgical management.119 
  Not all fistulas require surgery. Although intestinal fis-
tulas occur in one-third of CD patients, only a few pa-
tients require surgical management.120 Generally, fistulas 
associated with abscesses or strictures, that are connected 
to the genitourinary tract, or that cause intestinal mal-
absorption are indications for surgical management. 
  The lifetime risk for intraabdominal abscess in CD pa-
tients is approximately 25%.121 Almost all abscesses re-
quire drainage either surgically or percutaneously. 
Although there is controversy as to whether or not intra-
abdominal CD abscess should be managed surgically, sur-
gical resection is required when an abscess has enteric 
contents.122 Korean data have shown that nonsurgical 
treatment including percutaneous catheter drainage can be 
considered an initial therapy for a CD-related abscess. 
The overall success rate and cumulative recurrence rate at 
seven months were 66.7% and 12.5%, respectively.16 A 
recent Korean study reported that the clinical efficacy of 
nonsurgical treatment is comparable to that of surgical 
treatment.123 Other indications for surgical management 
in CD include free perforation, bleeding and cancer. 
  In CD, 70-90% of patients will require surgical manage-
ment during the disease course. Another study reported 
that the cumulative operation rate was 44%, 61%, and 
71% at one, five, and 10 years after diagnosis, 
respectively.124 Unlike the above Western studies, the rate 
was much lower in the results of a Korean study with 
11.5%, 13.1%, and 18.2% at one, three, and six years af-
ter diagnosis, respectively.36 The rate reported in another 
Korean study was also lower than that reported for 
Western countries.125 This disparity could be attributed to 
the different perspectives of different backgrounds toward 
surgical intervention in CD patients. Another possible 
reason could be that the Western study was conducted 
early, when aggressive surgery for CD was prevalent and 
Korean studies are more recent, when surgical treatment 
is rarely performed due to the advances in medical 
treatment. 
  The rate of complications with surgical management for 
CD in Korea is 13.6%, which is comparable to that of 
other countries.126 
ULCERATIVE COLITIS
1. Medical management
  UC can be treated according to anatomical extent of 
the disease. In distal UC, in which disease involvement is 
limited to below the splenic flexure, a topical agent can 
be effectively applied. Similar to CD, the management of 
UC is focused on both induction and maintenance of dis-
ease remission. In addition, the therapeutic decision de-
pends mainly on clinical severity rather than on histologic 
severity of inflammation. 
1) Induction of remission
  In mild to moderate active UC patients, the first line 
regimen is 5-ASA, including oral and rectal formulations. 
Effective oral doses for each drug are as follows; sulfasa-
lazine 4-6 g/day, mesalamine 2-4 g/day, balsalazide 6.75 
g/day, olsalazine 1.5-3 g/day. The effects of these drugs 
are usually observed within 2-4 weeks in 40-80% of 
patients.127,128 Left side colitis can also be managed with 
topical agents such as rectal mesalazine or rectal 
corticosteroid. Controlled trials show that topical mesal-
amine is superior to oral 5-ASA or topical corticosteroid 
alone in inducing clinical improvement in patients with 
mild to moderate distal colitis.110,129,130 Furthermore, the 
combination of oral and topical 5-ASA may produce a 
better response in the management of mild to moderate 
distal colitis than administration of either oral or topical 
formulations alone.131 
  If the patients fail to respond to 5-ASA agents, they 
should be managed with oral prednisone 40-60 mg daily 
for one to two weeks. At one year after starting cortico-
steroids, a prolonged response is observed in 49% of pa-
tients, and 22% of patients become steroid dependent.132 
  Patients with severe active UC showing aggravated 
symptoms despite treatment with oral corticosteroids 
should be hospitalized for intravenous steroid therapy. 
Further failure to respond to intravenous steroid might 
require the use of cyclosporine, tacrolimus and a biologic 
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Table 4. Characteristics of Korean Patients with CD Compared to Those of Western Countries
Differences Similarities
Epidemiology • Incidence and prevalence of CD in Korea are low, but are 
increasing rapidly whereas those of Western countries 
have stabilized or only slightly increased over time
1,28-31
 
• Male is predominant in the prevalence rate of CD in 
Korean population while female is predominant or equal 
to male in Western countries
1,28,32
• CD shows a trend of more accelerated 
incidence rate compared to UC
1
Genomics • CARD15 (NOD2) and ATG16L1 mutations were not 
found to be associated with susceptibility to CD
15,59,62
• Genetic variants in IL23R, TNFSF15, and 
TNF-α gene were associated with suscep-
tibility to CD
60-62
Diagnosis • Intestinal tuberculosis and intestinal Behcet’s disease 
should be included as a differential diagnosis because of 
their relatively high prevalence in Korean population
35,36
• Sensitivity and specificity of ASCA for CD 
are 49.4% and 79.2%, respectively
42
Clinical features • The most common location of CD is both small bowel 
and colon type in Korean population while isolated 
colonic disease is the most common type in Western 
countries
1
• The incidence rate of perianal fistulas in Korea is higher 
than Western countries (48.5% vs 13-38%)
13
Therapeutic efficacy • The most common reason for infliximab cessation was 
the limitation of the standard national health insurance 
reimbursement
99
• Korean patients who are treated with AZA/6-MP 
experience myelotoxicity more frequently than similarly 
treated Westerners
108
• The cumulative operation rate of Korean CD patients is 
much lower than that of Western CD patients
36,125
• The clinical response rate and clinical 
remission rate for infliximab in Korean 
luminal CD and fistular disease are similar 
with those of Western countries
99
• The rate of complications with surgical 
management for CD in Korea is comparable 
to that of Western countries
126
agent such as infliximab. If patients do not respond to 
maximal medical treatment, superimposed infection with 
cytomegalovirus or C. difficile should be considered as a 
potential cause of aggravation. 
  Although there have been many studies in Western 
countries indicating the usefulness of cyclosporine in the 
treatment of severe UC, the efficacy of cyclosporine has 
been disappointing in Korea, with a reported response 
rate of only 14%.133 One Korean study was conducted to 
evaluate the efficacy of cyclosporine and corticosteroid 
combination therapy in patients with severe UC that was 
refractory to an initial intravenous corticosteroid treat-
ment. Unlike Western studies, the Korean study con-
cluded that this combination failed to present any addi-
tional benefit over corticosteroid therapy alone in terms 
of short-term response.134 These results suggest that there 
might be differences in the metabolism of this agent or 
differences in phenotypes, in terms of responsiveness, 
based on differences in genetic backgrounds. 
  Korean UC patients seem to show a better clinical re-
sponse to medical treatment than their Western 
counterparts. The overall remission rate in the first attack 
was 90% in Western population-based studies, whereas 
the rate in the Korean study with 311 first diagnosed UC 
patients was 97.4%.20 
2) Maintenance management
  5-ASA agents are the mainstay of effective treatment 
for relapse-prevention of UC. Topical 5-ASA reduces the 
relapse rates in proctitis or left sided colitis, but topical 
corticosteroids have not shown effectiveness as a main-
tenance treatment in distal colitis.127,135,136 AZA or 6-MP 
may be another choice for relapse-prevention in patients 
who do not respond to 5-ASA or who are dependent on 
oral steroids. Patients, who have frequent relapses or are 
steroid-dependent, despite treatment with 5-ASA and im-
munomodulators, can be treated effectively with inflixi-
mab. Recent studies have shown that 45% of infliximab 
responders remain in the non-relapsed state, compared to 
20% of initial responders in the placebo group after 54 
weeks of maintenance therapy with infliximab.137 These 
promising results with infliximab encourage further trials 
for confirmation of the role of infliximab as an effective 
management of UC. 
2. Surgical management
  A surgical approach is required for treatment of UC 
when there are life-threatening complications such as 
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Table 5. Characteristics of Korean Patients with UC Compared to Those of Western Countries
Differences Similarities
Epidemiology • Incidence and prevalence of UC in Korea are low, but 
are increasing rapidly whereas those of Western 
countries have stabilized or only slightly increased over 
time
1,28-31
• Male to female ratio of the in Korean UC 
patients was 0.94:1
20
Genomics • HLA-DRB1*1502 allele was associated with UC in 
Korean population
65
Diagnosis • The prevalence of pANCA in Korean UC patients was 
relatively low compared to those in Western countries 
(22% vs 59-84%)
17
• Sensitivity and specificity of pANCA for UC 
are 44.2% and 95.8%, respectively, which 
are similar to those in Western countries
42
Clinical features • The extent and severity of disease at 
diagnosis in Korean UC patients was similar 
to that in Western countries
20
Therapeutic efficacy • The efficacy of cyclosporine has been disappointing in 
Korea with a response rate of only 14%
133
• Korean UC patients seem to show a better clinical 
response to medical treatment than their Western 
counterparts (97.4% vs 90%)
20
• The cumulative colectomy rate is much lower in Korean 
UC patients than that in Western patients
17,20
• The rate of pouchitis after IPAA in Korean 
UC patients was similar to that in Western 
patients (37.5% vs 24-48%)
141
hemorrhage or perforation, and documented dysplasia or 
cancer. Other indications for surgery include fulminant 
colitis with or without toxic megacolon refractory to max-
imal medical management or intolerance to immuno-
suppression or medical therapy. Growth failure due to in-
tractable disease course in pediatric UC patients can also 
be an indication for surgery.138 Since 20-24% of strictures 
in UC are malignant139 and biopsies of the stricture site 
are inadequate for excluding malignancy, strictures should 
be managed with surgery.140 
  Total proctocolectomy with ileal J-pouch anal anasto-
mosis (IPAA) is the most commonly used surgical meth-
od for treatment of UC. Large cohort studies have de-
scribed this method as relatively safe and durable with a 
low perioperative mortality rate of 0.2-1.0%. In a recent 
study of 20 Korean UC patients treated with IPAA, post-
operative functional outcomes including sexual and uri-
nary function were found to be tolerable. Despite a rela-
tively high postoperative complication rate (35%), most 
cases were managed conservatively.14 
  Pouchitis is the most common long-term complication 
of IPAA. It develops in 24-48% of IPAA patients and can 
be controlled with antibiotics including ciprofloxacin or 
metronidazole. Similar to data from other countries, 
37.5% of Korean UC patients undergoing total proctoco-
lectomy with IPAA have pouchitis and most of these cas-
es occur within one year after surgery.141 
  One of the unique characteristics is that the cumulative 
probability of colectomy is much lower in Korean UC pa-
tients than in Western patients. In Western countries, the 
cumulative colectomy rate is shown to be 3-10% after 
one year,142-144 8-20% after five years,144,145 and 24-34% 
after 10 years.146,147 In contrast, studies from Korea reveal 
that it is 2.0-3.0% after one year and 3.3% after five to 
15 years.17,20 Furthermore, the author showed that there 
were no deaths associated with UC in that study, sug-
gesting that Korean UC patients tend to have a milder 
form of the disease. 
CONCLUSION
  Although IBD is a worldwide disease, its incidence 
rates and clinical features vary depending on geographic 
area and population origin. The incidence and the preva-
lence rates of IBD have been increasing dramatically in 
Korea. There are some clinical and genotypic character-
istics that are unique to Korean IBD patients (Tables 4 
and 5). Most of all, the clinical course of IBD in Korean 
patients seems milder than that in Western countries, as 
indicated by the lower rates of surgical intervention and 
better responses to medical management in Korean 
patients. These differing characteristics may provide sig-
nificant clues about the etiology and the pathophysiology 
of IBD. Further comprehensive population-based studies 
are required to clarify these differences. 
  Although biological therapies have shown a promising 
role and have altered the management of IBD, they must 
be used judiciously based on the existing evidence of effi-
cacy and safety. The recent emergence of several promis-
ing biologic agents suggests that these novel biologic 
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agents may replace or be used in combination with TNF 
antagonists in the near future. 
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